|
WASHINGTON, DC USA -- PHARMA UPDATE NEWS SERVICE™ -- OCTOBER 19, 2017: Our feature article this month is a review of the FDA's recent guidance on OFF-LABEL communications. We also begin a two-part series on STATE and LOCAL activities to regulate the pharmaceutical industry starting with a look at PRICING TRANSPARENCY initiatives. Commercial interactions with PATIENTS and PATIENT ADVOCACY groups is next followed by the latest developments with Ohio's DRUG SAMPLE VERIFICATION rules. We round out the month with the latest on ENFORCEMENT and WHISTLEBLOWERS.
FEATURE:
-
The Never-Ending Saga of Off-label Promotion
Jenny McVey, Associate Director, FRA Life Sciences
ISSUE ARTICLES:
-
Coming Soon to a State or Even City Near You - Part 1 Pricing Transparency
Nicodemo (Nico) Fiorentino, Esq., Manager, Research & Compliance, for G&M Health LLC
-
The Expanding Frontier - Commercial Interactions with Patients and Patient Organizations
David Davidovic, Founder, pathForward; former Global VP, Commercial Services, Genentech and Roche
-
UPDATE: Round 2 with Ohio's Drug Sample Verification Requirements
Nicodemo (Nico) Fiorentino, Esq., Manager, Research & Compliance, for G&M Health LLC, Bryan Andrews, Director of Sales Operations, MedPro Systems LLC
-
Getting Serious About Fraud - The DOJ Charges 412
Kaitlin Fallon Wildoner, Esq., Senior Staff Writer, Life Science Compliance Update
-
Will Your Whistle Be Heard at Home?
Sally Foroughi, Staff Writer, Life Science Compliance Update
The abstracts for all of the following articles can be read by clicking here.
Subscribe Now
Purchase October Issue
Thank you for relying on Life Science Compliance Update to keep you up-to-date on the pharmaceutical, biotechnology, and device manufacturing industries.
|
